A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults
NCT ID: NCT01160172
Last Updated: 2017-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
88 participants
INTERVENTIONAL
2010-07-19
2012-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
NCT03170609
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
NCT01150123
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
NCT04420221
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age
NCT00645346
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
NCT02804711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Staphylococcal investigational vaccine GSK2392103A
intramuscular vaccination according to protocol schedule
Group B
Staphylococcal investigational vaccine GSK2392105A
intramuscular vaccination according to protocol schedule
Group C
Staphylococcal investigational vaccine GSK2392106A
intramuscular vaccination according to protocol schedule
Group D
Staphylococcal investigational vaccine GSK2392019A
intramuscular vaccination according to protocol schedule
Group E
Saline placebo
intramuscular vaccination according to protocol schedule
Group F
Saline placebo
intramuscular vaccination according to protocol schedule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Staphylococcal investigational vaccine GSK2392103A
intramuscular vaccination according to protocol schedule
Staphylococcal investigational vaccine GSK2392105A
intramuscular vaccination according to protocol schedule
Staphylococcal investigational vaccine GSK2392106A
intramuscular vaccination according to protocol schedule
Staphylococcal investigational vaccine GSK2392019A
intramuscular vaccination according to protocol schedule
Saline placebo
intramuscular vaccination according to protocol schedule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A male or female between 18 and 40 years of age, inclusive, at the time of first vaccination.
* Written informed consent obtained from the subject.
* Healthy subjects as established by medical history, clinical examination and laboratory assessment before entering into the study.
* Female subjects of non-childbearing potential may be enrolled in the study.
* Female subjects of childbearing potential may be enrolled in the study, if the subject:
* has practiced adequate contraception for 30 days prior to vaccination, and
* has a negative pregnancy test at Screening, and
* has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series
Exclusion Criteria
* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.
* Any clinically significant acute or chronic, local or systemic infection, proven or suspected to be caused by Staphylococcus aureus and requiring antibiotic treatment, within the 6 months preceding the first vaccination.
* Previous administration of any investigational Staphylococcus aureus vaccine/antibodies.
* History of; or current bleeding or coagulation disorder.
* Known or suspected reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
* History of; or current autoimmune or other immune-mediated disease.
* Administration or planned administration, of any vaccine not foreseen by the study protocol within 30 days of the first dose of vaccines up to 1 month after the last vaccine dose.
* Administration of immunoglobulins and/or any blood products within the last 3 months preceding the first dose of study vaccine or planned administration during the study period.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
* Any clinically relevant abnormal haematological or biochemical or urine laboratory values at screening.
* Any acute or chronic, clinically significant disease, as determined by physical examination or laboratory screening tests.
* Acute disease and/or fever at study entry.
* Pregnant or lactating female.
* Female planning to become pregnant or planning to discontinue contraceptive precautions.
* History of; or current alcoholism and/or drug abuse.
* Any other condition that the principal investigator judges may interfere with study findings.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
La Louvière, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S, Van Belle P, Boutriau D. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. Hum Vaccin Immunother. 2015;11(3):620-31. doi: 10.1080/21645515.2015.1011021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
113949
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.